Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting this week. The study was conducted using our mouse surrogate molecule in an in-house developed mouse model of NASH with elevated hepatic HSD expression. HSD17B13 is a genetically identified target strongly associated with liver steatosis and fibrosis. However the mode of action still remains unknown and very little preclinical reversibility data has been shown up to now. Ribo’s HSD program is a siRNA molecule based on our proprietary Ribo-GalSTAR delivery system and is about to enter IND-enabling phase.
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals
